论文部分内容阅读
目的观察多西他赛联合卡铂治疗晚期鼻咽癌的临床疗效及安全性。方法 39例晚期鼻咽癌患者给予多西他赛联合卡铂治疗,多西他赛75 mg.m-2,静脉滴注,卡铂400 mg.m-2,静脉滴注,28天为1个周期,治疗2周期以上。结果 39例患者中,完全缓解4例,部分缓解23例,稳定9例,进展3例,总有效率为69.2%。39例患者中,中位生存期18.3月,1年生存率为73.3%。最常见的不良反应为骨髓抑制,Ⅲ～Ⅳ度白细胞和血小板下降发生率分别为30.8%和10.2%,其余均轻微,可耐受。结论多西他赛联合卡铂治疗晚期鼻咽癌有较好的疗效,且毒性可以耐受。
Objective To observe the clinical efficacy and safety of docetaxel combined with carboplatin in the treatment of advanced nasopharyngeal carcinoma. Methods Thirty-nine patients with advanced nasopharyngeal carcinoma were treated with docetaxel plus carboplatin, docetaxel 75 mg.m-2, intravenous drip, carboplatin 400 mg.m-2, intravenous drip, 28 days were 1 Cycles, treatment 2 cycles or more. Results Of the 39 patients, 4 were complete remission, 23 were partial remission, 9 were stable, and 3 progressed. The total effective rate was 69.2%. Among the 39 patients, the median survival period was 18.3 months, and the 1-year survival rate was 73.3%. The most common adverse reaction was myelosuppression. The incidence of white blood cell and platelet decline in grades III to IV was 30.8% and 10.2%, respectively. The rest were mild and tolerable. Conclusion Docetaxel combined with carboplatin has good efficacy in the treatment of advanced nasopharyngeal carcinoma, and the toxicity can be tolerated.